ZSP-1603

N/A

Report date: 2022/05/31 15:48:40
NME

Base Information

Drug NameZSP-1603
Drug Alias NameZSP-1603
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor antagonistsFibroblast growth factor receptors antagonistsPlatelet-derived growth factor receptor beta inhibitors +[5] 
TargetsVascular endothelial growth factor receptorFibroblast growth factor receptorsPlatelet-derived growth factor receptor beta +[5] 
Therapy Area/IndicationsSolid tumoursIdiopathic Pulmonary FibrosisCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesWuxi Apptec Co LtdGuangdong Zhongsheng Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWuxi Apptec Co LtdGuangdong Zhongsheng Pharmaceutical Co LtdGuangdong Raynovent Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary FibrosisCarcinoma, Non-Small-Cell LungThyroid Neoplasms +[7] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A